EH3
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. … Read more
EH3 (EH3) - Net Assets
Latest net assets as of September 2025: €458.89 Million EUR
Based on the latest financial reports, EH3 (EH3) has net assets worth €458.89 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€659.81 Million) and total liabilities (€200.92 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €458.89 Million |
| % of Total Assets | 69.55% |
| Annual Growth Rate | -10.01% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1.99 |
EH3 - Net Assets Trend (2021–2024)
This chart illustrates how EH3's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EH3 (2021–2024)
The table below shows the annual net assets of EH3 from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €486.18 Million | -11.94% |
| 2023-12-31 | €552.10 Million | -7.26% |
| 2022-12-31 | €595.33 Million | -10.76% |
| 2021-12-31 | €667.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to EH3's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 24709800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.15 Billion | 443.20% |
| Total Equity | €486.18 Million | 100.00% |
EH3 Competitors by Market Cap
The table below lists competitors of EH3 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WAAREE RENEWABLE TECHNOLOGIES LTD
NSE:WAAREERTL
|
$245.45 Million |
|
Zhejiang Dilong New Material Co Ltd
SHE:002247
|
$245.48 Million |
|
Docebo Inc
NASDAQ:DCBO
|
$245.55 Million |
|
Villeroy und Boch AG Pfd.
LSE:0OPA
|
$245.56 Million |
|
Egis Technology
TWO:6462
|
$245.37 Million |
|
Candel Therapeutics Inc
NASDAQ:CADL
|
$245.32 Million |
|
PetroTal Corp
OTCQX:PTALF
|
$245.14 Million |
|
SYLVANIA PLAT. DL 001
F:31L
|
$245.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EH3's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 552,097,000 to 486,176,000, a change of -65,921,000 (-11.9%).
- Net loss of 82,183,000 reduced equity.
- Other factors increased equity by 16,262,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-82.18 Million | -16.9% |
| Other Changes | €16.26 Million | +3.34% |
| Total Change | €- | -11.94% |
Book Value vs Market Value Analysis
This analysis compares EH3's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 7.73x to 11.01x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.68 | €13.00 | x |
| 2022-12-31 | €1.47 | €13.00 | x |
| 2023-12-31 | €1.35 | €13.00 | x |
| 2024-12-31 | €1.18 | €13.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EH3 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -35.95%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.41x
- Recent ROE (-16.90%) is below the historical average (-11.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 1.16% | 1.33% | 0.55x | 1.60x | €-58.98 Million |
| 2022 | -17.77% | -28.66% | 0.42x | 1.49x | €-165.34 Million |
| 2023 | -10.71% | -19.26% | 0.37x | 1.51x | €-114.32 Million |
| 2024 | -16.90% | -35.95% | 0.33x | 1.41x | €-130.80 Million |
Industry Comparison
This section compares EH3's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $653,855,333,333
- Average return on equity (ROE) among peers: -12.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EH3 (EH3) | €458.89 Million | 1.16% | 0.44x | $245.45 Million |
| Bayer Aktiengesellschaft (BAYA) | $30.70 Billion | -34.19% | 2.81x | $9.78 Billion |
| JCR Pharmaceuticals Co., Ltd. (JCR) | $47.44 Billion | -10.03% | 1.21x | $237.56 Million |
| Otsuka Holdings Co. Ltd (OS1) | $1.88 Trillion | 7.87% | 0.40x | $26.35 Billion |